Bull
$7.26
Scenario price
$13.840
+0.050 (+0.36%)At close
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Bioventus Inc is a good buy right now due to its current price of $13.84 being significantly lower than the analyst price target of $18, indicating a potential upside of 30.4%. Additionally, the company has shown strong financial performance with a gross margin of 68.29% in Q2 2026 and a year-to-date change of +91.96%, suggesting robust growth. The main risk is the recent 5-day change of -3.76%, indicating short-term volatility.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bravura Solutions Reports Significant Revenue Growth

Biotech Stocks Reach 52-Week Highs Driven by Earnings

Bioventus Q2 2026 Earnings Call Highlights

Bioventus Q2 Earnings Report Analysis

Bioventus Reports Significant Earnings Growth in Q2
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Bioventus Inc is a good buy right now due to its current price of $13.84 being significantly lower than the analyst price target of $18, indicating a potential upside of 30.4%. Additionally, the company has shown strong financial performance with a gross margin of 68.29% in Q2 2026 and a year-to-date change of +91.96%, suggesting robust growth. The main risk is the recent 5-day change of -3.76%, indicating short-term volatility.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.